trending Market Intelligence /marketintelligence/en/news-insights/trending/N48qDc7Po17tycNiWeFuUg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Moderna's metabolic disorder drug granted expedited US FDA review

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Moderna's metabolic disorder drug granted expedited US FDA review

Moderna Inc. has received the U.S. Food and Drug Administration's fast track designation for its rare metabolic disorder drug.

The fast track designation accelerates the review of therapies and vaccines for serious conditions. Drug programs with the fast track tag may benefit from early and frequent communication with the FDA as well as a rolling submission of the marketing application.

The U.S. regulator awarded the fast track designation for the company's investigational drug mRNA-3927 for the treatment of propionic acidemia, a rare inherited metabolic disorder characterized by the deficiency of an enzyme involved in the digestion of certain proteins. Moderna said in an Oct. 22 press release that the disease has no currently approved treatments for its underlying cause.

Cambridge, Mass.-based Moderna plans to start a phase 1/2 study of the drug to treat primarily pediatric patients with propionic acidemia in the U.S. and Europe.

Moderna's mRNA-3927 therapy was previously granted the orphan drug and rare pediatric disease designations from the FDA and orphan designation by the European Medicines Agency.